The Horizon Ahead
- 22 May 2026
- journal article
- review article
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 55 (3) , 573-580
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Current status and future perspectives of FGF21 analogues in clinical trialsTrends in Endocrinology & Metabolism, 2024
- Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialNature Medicine, 2022
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort studyThe Lancet, 2018
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathwayProceedings of the National Academy of Sciences, 2015
- Adjunctive Therapy with Pramlintide Lowers HbA1c without Concomitant Weight Gain and Increased Risk of Severe Hypoglycemia in Patients with Type 1 Diabetes Approaching Glycemic TargetsExperimental and Clinical Endocrinology & Diabetes, 2005